These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Epidemiology and current treatment of multiple sclerosis in Europe today. Pozzilli C; Romano S; Cannoni S J Rehabil Res Dev; 2002; 39(2):175-85. PubMed ID: 12051462 [TBL] [Abstract][Full Text] [Related]
23. Multiple sclerosis. Part 2: ophthalmic issues in MS therapy. Pula JH; Javed A Curr Opin Ophthalmol; 2009 Nov; 20(6):476-81. PubMed ID: 19816177 [TBL] [Abstract][Full Text] [Related]
24. Disease-modifying drugs for the early treatment of multiple sclerosis. Flachenecker P Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542 [TBL] [Abstract][Full Text] [Related]
26. Interferons in multiple sclerosis: ten years' experience. Tourbah A; Lyon-Caen O Biochimie; 2007; 89(6-7):899-902. PubMed ID: 17574320 [TBL] [Abstract][Full Text] [Related]
27. Current disease-modifying therapies in multiple sclerosis. Kieseier BC; Hartung HP Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379 [TBL] [Abstract][Full Text] [Related]
28. Immunomodulatory therapy in multiple sclerosis and breast cancer risk: a case report and literature review. Amaria RN; Corboy JR; Finlayson CA; Robinson WA; Borges VF Clin Breast Cancer; 2008 Oct; 8(5):449-52. PubMed ID: 18952560 [TBL] [Abstract][Full Text] [Related]
29. Diagnosis and disease modifying treatments in multiple sclerosis. Zajicek J Postgrad Med J; 2005 Sep; 81(959):556-61. PubMed ID: 16143683 [TBL] [Abstract][Full Text] [Related]
30. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience. Pozzilli C; Prosperini L; Sbardella E; De Giglio L; Onesti E; Tomassini V Neurol Sci; 2005 Dec; 26 Suppl 4():S174-8. PubMed ID: 16388353 [TBL] [Abstract][Full Text] [Related]